Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Final Analysis of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial-Reference-Cited by-同舟云学术

Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Final Analysis of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial

Published:2021-09 Issue:9 Volume:76 Page:535-536
ISSN:1533-9866
Container-title:Obstetrical & Gynecological Survey
language:en
Short-container-title:

Author:

Poveda Andrés,Floquet Anne,Ledermann Jonathan A.,Asher Rebecca,Penson Richard T.,Oza Amit M.,Korach Jacob,Huzarski Tomasz,Pignata Sandro,Friedlander Michael,Baldoni Alessandra,Park-Simon Tjoung-Won,Tamura Kenji,Sonke Gabe S.,Lisyanskaya Alla,Kim Jae-Hoon,Filho Elias Abdo,Milenkova Tsveta,Lowe Elizabeth S.,Rowe Phil,Vergote Ignace,Pujade-Lauraine Eric,

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Obstetrics and Gynaecology,General Medicine

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Feasibility and cost-effectiveness of genetic counselling for all patients with newly diagnosed ovarian cancer: a single-centre retrospective study;Swiss Medical Weekly;2024-04-15

2. BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges;Frontiers in Oncology;2024-03-13

3. PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials;Journal of Ovarian Research;2024-02-26

4. Թիրախային թերապիայի և իմունաթերապիայի դերը ռեցիդիվող ձվարանների քաղցկեղի բուժման մեջ;Medical Science of Armenia;2023-12-10

5. Analysis of olaparib efficacy in patients with serous ovarian cancer;Hirurg (Surgeon);2023-08-29